<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225520</url>
  </required_header>
  <id_info>
    <org_study_id>S64188_v3.0</org_study_id>
    <nct_id>NCT04225520</nct_id>
  </id_info>
  <brief_title>Mechanical Dyssynchrony as Selection Criterion for CRT</brief_title>
  <acronym>AMEND-CRT</acronym>
  <official_title>Assessment of MEchaNical Dyssynchrony as Selection Criterion for Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous experience with cardiac resynchronization therapy (CRT) candidates suggests that&#xD;
      selection of these patients can be improved. Current clinical guideline approaches are mainly&#xD;
      too unspecific and lead to a high non-responder rate of 30-40%, which causes a burden on&#xD;
      health care systems and puts patients at risk of an unnecessary treatment who might benefit&#xD;
      more from a conservative approach. Previous work indicated that using the assessment of&#xD;
      mechanical dyssynchrony on echocardiography can lower the non-responder rate at least by 50%&#xD;
      without compromising sensitivity for detecting amendable patients. The current prospective,&#xD;
      randomized, multi-center trial was therefore designed to prove that the characterization of&#xD;
      the mechanical properties of the left ventricle can improve patient selection for CRT.&#xD;
      Patients will be randomized into one of two study arms: a control study arm with treatment&#xD;
      recommendation based on clinical guidelines criteria, or an experimental study arm with&#xD;
      treatment recommendation based on the presence of mechanical dyssynchrony. All patients will&#xD;
      receive a CRT implantation. In the control study arm, bi-ventricular pacing will be turned&#xD;
      on. In the experimental study arm, bi-ventricular pacing will be turned on or off, depending&#xD;
      on the presence or absence of mechanical dyssynchrony, respectively. The primary endpoint&#xD;
      will be non-inferiority in outcome of a treatment recommendation based on mechanical&#xD;
      dyssynchrony, achieved with a lower number of CRT devices implanted, effectively leading to a&#xD;
      lower number needed to treat. Outcome measures are the average relative change in&#xD;
      continuously measured LVESV per arm and the percentage 'worsened' according to the Packer&#xD;
      Clinical Composite Score per arm after 1 year follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume response and Packer Clinical Composite Score</measure>
    <time_frame>12 months follow-up</time_frame>
    <description>Non-inferiority in outcome of a treatment recommendation based on mechanical dyssynchrony, achieved with a lower number of CRT devices implanted, effectively leading to a lower number needed to treat. Outcome measures are the average relative change in continuously measured left ventricular end-systolic volume per arm and the percentage 'worsened' according to the Packer Clinical Composite Score per arm after 12 months follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on left ventricular function in both arms</measure>
    <time_frame>12 months follow-up</time_frame>
    <description>≥ 10% difference in relative change in left ventricular ejection fraction and/or&#xD;
≥1.5% difference in absolute change in global longitudinal strain and/or&#xD;
improvement in myocardial work from baseline to month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in quality of life as measured by the Minnesota Living with Heart Failure questionnaire score and EuroQol 5D index score in both arms</measure>
    <time_frame>12 months follow-up</time_frame>
    <description>≥ 5 points difference in change on the Minnesota Living with Heart Failure questionnaire score and/or&#xD;
≥0.08 points difference in change on the EuroQol 5D index score from baseline to month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in 6 minute walk test distance in both arms</measure>
    <time_frame>12 months follow-up</time_frame>
    <description>≥ 45 meters difference in change from baseline to month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in predictive value for volume response</measure>
    <time_frame>12 months follow-up</time_frame>
    <description>≥15% relative reduction in left ventricular end-systolic volume from baseline to month 12 will be considered as a response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in predictive value for long-term patient outcome in both arms</measure>
    <time_frame>1 year, 3 years and 5 years follow-up</time_frame>
    <description>Cox's proportional hazards model:&#xD;
At 1 year for 'worsened' PCCS&#xD;
At 3 and 5 years for cardiovascular mortality and heart failure hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in long-term patient outcome in both arms</measure>
    <time_frame>3 years and 5 years follow-up</time_frame>
    <description>Kaplan Meier survival analysis for heart failure hospitalization&#xD;
Kaplan Meier survival analysis for cardiovascular mortality&#xD;
Kaplan Meier survival analysis for combined heart failure hospitalization and cardiovascular mortality&#xD;
Kaplan Meier survival analysis for all-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Left Ventricular Dyssynchrony</condition>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathy, Dilated</condition>
  <condition>Cardiac Remodeling, Ventricular</condition>
  <arm_group>
    <arm_group_label>Treatment recommendation based on guidelines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of the patient assigned to this arm will be based on the current guidelines for CRT implantation, as issued by the European Society of Cardiology. All patients will receive CRT implantation, with bi-ventricular pacing ON.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment recommendation based on mechanical dyssynchrony</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of the patients assigned to this arm will be based on the presence of mechanical dyssynchrony. All patients will receive CRT implantation. Bi-ventricular pacing will be either turned ON or OFF, based on respectively the presence or absence of mechanical dyssynchrony.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac resynchronization therapy ON</intervention_name>
    <description>Implantation of a CRT device. Bi-ventricular pacing will be turned ON.</description>
    <arm_group_label>Treatment recommendation based on guidelines</arm_group_label>
    <arm_group_label>Treatment recommendation based on mechanical dyssynchrony</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac resynchronization therapy OFF</intervention_name>
    <description>Implantation of a CRT device. Bi-ventricular pacing will be turned OFF.</description>
    <arm_group_label>Treatment recommendation based on mechanical dyssynchrony</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The proposed inclusion criteria represent the minimum recommendations for CRT implantation&#xD;
        in heart failure patients according to the ESC 2016 guidelines. In addition:&#xD;
&#xD;
          1. Patient has a LVEF ≤ 35%&#xD;
&#xD;
          2. Patient has a LVEDD ≥ 55mm&#xD;
&#xD;
          3. Patient has been in a stable medical condition for ≥ 1 month prior inclusion&#xD;
&#xD;
          4. Patient receives Optimal Medical Treatment (OMT)&#xD;
&#xD;
          5. Patient underwent complete revascularization in case of ischemia&#xD;
&#xD;
          6. Patients is able to understand and willing to provide a written informed consent&#xD;
&#xD;
          7. Patient is 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the following criteria will not participate in the study:&#xD;
&#xD;
          1. Patient suffers from ventricular arrhythmias which do not allow to acquire 3&#xD;
             consecutive regular beats during echocardiography (e.g. frequent VES, bigemini, …)&#xD;
&#xD;
          2. Patient suffers from severe MR, or otherwise more than moderate valvular disease&#xD;
&#xD;
          3. Patient suffers from unstable angina&#xD;
&#xD;
          4. Patient suffers from pulmonary hypertension, other than secondary to left heart&#xD;
             disease&#xD;
&#xD;
          5. Patient has a life expectancy of less than 1 year&#xD;
&#xD;
          6. Patient is pregnant or breastfeeding&#xD;
&#xD;
          7. Patient has either no pacemaker / ICD or has a right ventricular pacing of &lt; 40%, and&#xD;
             any of the following:&#xD;
&#xD;
               1. Atrial fibrillation&#xD;
&#xD;
               2. PR duration &gt; 250ms&#xD;
&#xD;
               3. Second or third degree atrioventricular block&#xD;
&#xD;
               4. Intrinsic QRS duration &lt; 130ms&#xD;
&#xD;
          8. Patient has a right ventricular pacing of &gt; 40% and any of the following&#xD;
&#xD;
               1. Sensed AV delay &gt; 250ms&#xD;
&#xD;
               2. Paced AV delay &gt; 280ms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens-Uwe Voigt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens-Uwe Voigt, MD, PhD</last_name>
    <phone>+32 16 34 90 16</phone>
    <email>jens-uwe.voigt@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexis Puvrez, MD</last_name>
    <phone>+32 16 34 58 43</phone>
    <email>alexis.puvrez@kuleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Seghers</last_name>
      <email>johanna.seghers@uza.be</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Brosens</last_name>
      <email>nathalie.brosens@uza.be</email>
    </contact_backup>
    <investigator>
      <last_name>Johan Saenen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgard Prihadi, MD</last_name>
      <email>edgard.prihadi@zna.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Gayet</last_name>
      <email>Frederic.Gayet@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Daniela Mirica, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie Willems</last_name>
      <email>Anne-Marie.Willems@azmmsj.be</email>
    </contact>
    <investigator>
      <last_name>Nico Van De Veire, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter Vervaet</last_name>
      <email>Pieter.Vervaet@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Frank Timmermans, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Puvrez, MD</last_name>
      <phone>0032 16 34 58 43</phone>
      <email>alexis.puvrez@kuleuven.be</email>
    </contact>
    <investigator>
      <last_name>Jens-Uwe Voigt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Ostend</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tineke Vandeputte</last_name>
      <email>tvandeputte@azdamiaan.be</email>
    </contact>
    <investigator>
      <last_name>Stefan Ketels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tessy Van Tomme</last_name>
      <email>Tessy.VanTomme@azdelta.be</email>
    </contact>
    <investigator>
      <last_name>Karl Dujardin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupements des hôpitaux de l'institut catholique de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59800 Lille</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothée Brzyski</last_name>
      <email>Brzyski.Dorothee@ghicl.net</email>
    </contact>
    <investigator>
      <last_name>Sylvestre Maréchaux, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Pontchaillou Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleonore Serrano</last_name>
      <email>eleonore.serrano@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Erwan Donal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vinzenz-Hospital</name>
      <address>
        <city>Köln</city>
        <zip>50733</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Simons</last_name>
      <email>judith.simons@cellitinnen.de</email>
    </contact>
    <contact_backup>
      <last_name>Doris Balling</last_name>
      <email>doris.balling@cellitinnen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Winter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Wad Wrodzonych Serca</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolina Plaskota, MD</last_name>
      <email>kplaskota@ikard.pl</email>
    </contact>
    <investigator>
      <last_name>Miroslaw Kowalski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Institute Nicolae Stancioiu</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400001</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Razvan Mada, MD</last_name>
      <email>mada_razvan@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ruxandra Beyer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Jens-Uwe Voigt, MD, PhD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Cardiac resynchronization therapy</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Mechanical dyssynchrony</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Apical rocking</keyword>
  <keyword>Septal flash</keyword>
  <keyword>Left ventricle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Available upon reasonable request after acceptance of publications.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

